scholarly journals m6A-induced LINC00958 promotes breast cancer tumorigenesis via the miR-378a-3p/YY1 axis

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Dongwen Rong ◽  
Qian Dong ◽  
Huajun Qu ◽  
Xinna Deng ◽  
Fei Gao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Human Breast Cancer ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Human Breast ◽  
Transcript Stability ◽  
Rna Transcript ◽  
Insight Into ◽  
Competitive Endogenous Rna

AbstractIncreasing evidence demonstrates that long noncoding RNAs (lncRNAs) play critical roles in human breast cancer (BC) tumorigenesis. However, the mechanisms by which lncRNA and N6-methyladenosine (m6A) regulate BC tumorigenesis are still unclear. In the present research, LINC00958 was markedly overexpressed in BC tissue and cells, and LINC00958 upregulation promoted the tumor progression of BC cells. Mechanistically, m6A methyltransferase-like 3 (METTL3) gave rise to the upregulation of LINC00958 by promoting its RNA transcript stability. Moreover, LINC00958 acted as a competitive endogenous RNA for miR-378a-3p to promote YY1. Overall, these data provide novel insight into how m6A-mediated LINC00958 regulates BC tumorigenesis.

scholarly journals Long noncoding RNAs in regulation of human breast cancer: Table 1

2015 ◽  
Vol 15 (3) ◽  
pp. 222-226 ◽  
Author(s):  
Guangxue Wang ◽  
Cuicui Liu ◽  
Shengqiong Deng ◽  
Qian Zhao ◽  
Tieyan Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Human Breast

scholarly journals Effects of Simultaneous Knockdown of HER2 and PTK6 on Malignancy and Tumor Progression in Human Breast Cancer Cells

2013 ◽  
Vol 11 (4) ◽  
pp. 381-392 ◽  
Author(s):  
Natalie Ludyga ◽  
Natasa Anastasov ◽  
Michael Rosemann ◽  
Jana Seiler ◽  
Nadine Lohmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast

scholarly journals HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

2014 ◽  
Vol 9 (3) ◽  
pp. 586-600 ◽  
Author(s):  
Delphine R. Boulbes ◽  
Stefan T. Arold ◽  
Gaurav B. Chauhan ◽  
Korina V. Blachno ◽  
Nanfu Deng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Human Breast Cancer ◽  
Kinase Domain ◽  
Response To Treatment ◽  
Human Breast ◽  
Her Family ◽  
Kinase Domain Mutations

scholarly journals The Antimalarial Drug Pyronaridine Inhibits Topoisomerase Ii In Breast Cancer Cells And Hinders Tumor Progression In-Vivo

2021 ◽  
Vol 08 ◽  
Author(s):  
Paulina J. Villanueva ◽  
Denisse A Gutierrez ◽  
Lisett Contreras ◽  
Karla Parra ◽  
Giulio Francia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Cancer Cells ◽  
Antimalarial Drug ◽  
Human Breast Cancer ◽  
Topoisomerase Ii ◽  
Human Breast ◽  
Topoisomerase Ii Inhibitor

Background: Breast cancer is the most frequently diagnosed cancer in women worldwide. Pyronaridine (PND), an antimalarial drug, was shown to exert anticancer activity on seventeen different human cancer cells, seven from female breast tissue. Additionally, PND induced apoptosis via mitochondrial depolarization, alteration of cell cycle progression, and DNA intercalation. However, the molecular target of PND in cells was not elucidated. Objective: Here, we have further investigated PND's mode of action by using transcriptome analysis. Preclinical studies were also performed to determine whether PND could affect tumor progression in a human breast cancer xenograft in mice. Moreover, we assessed the combined efficacy of PND with well-known anticancer drugs. Methods: Transcriptome analyses of PND-treated cancer cells were performed. Topoisomerase II activity was evaluated by an in vitro assay. In addition, daily oral administration of PND was given to mice with human breast cancer xenografts. The differential nuclear staining assay measured in-vitro cell toxicity. Results: The transcriptome signatures suggested that PND might act as a topoisomerase II inhibitor. Thus, topoisomerase inhibition assays were performed, providing evidence that PND is a bona fide topoisomerase II inhibitor. Also, in-vivo studies suggest that PND hinders tumor progression. Besides, combination studies of PND with anticancer drugs Cisplatin and Gemcitabine revealed higher cytotoxicity against cancer cells than individual drug administration. Conclusion: The findings provide evidence that PND is a topoisomerase II inhibitor and can hinder cancer progression in an animal model, further demonstrating PND's favorable characteristics as a repurposed anticancer drug.

scholarly journals Inhibition of apoptosis in human breast cancer cells: Role in tumor progression to the metastatic state

2002 ◽  
Vol 101 (4) ◽  
pp. 317-326 ◽  
Author(s):  
Yolanda Fernández ◽  
Bin Gu ◽  
Antonio Martínez ◽  
Angels Torregrosa ◽  
Angels Sierra
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast
Sign in / Sign up

Export Citation Format

Share Document